[Didanosine as a capsule. A reliable drug in a new dosage form].
Ten years ago, the first clinical trial on the tolerability and efficacy of didanosine (ddl) was initiated in German therapeutic centers. At that time, AIDS patients in an advanced stage of the disease who failed to respond to monotherapy with AZT, were treated with ddl. However, the form of presentation of ddl, namely buffered powder, was poorly tolerated. In the meantime, galenical improvements have been made. Today, treatment with ddl is possible at a daily dose of one EC (enteric-coated) capsule. Given this in this form, the substance is highly effective, and the absorption of indinavir, ciprofloxacin, and ketoconazole is in no way impaired.
Jablonowski
H
H
Med Klinik am Städt Krankenhaus Salzgitter.
D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D016049:Didanosine / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010349:Patient Compliance; D013608:Tablets, Enteric-Coated
D019380:Anti-HIV Agents; D013608:Tablets, Enteric-Coated; D016049:Didanosine